



NEUROIMAGING in DEMENTIA

Prof. dr Philip Scheltens, FAAN, FEAN
Alzheimer Centrum Amsterdam



Disclosures

The Alzheimer Center VUmc has received funding from:

- *Aegon Nederland, VUmc Fonds, Heineken Nederland, Genootschap tot Steun Alzheimercentrum, Alzheimer Rally, Alzheimer Socks, NWO, ZonMW, CVON, EU-FP7, EU-JPND, EU-IMI, Alzheimer Nederland, Dioraphte, Gieskes Strijbis, Pasman Stichting and many others*

Prof Scheltens has provided consultancy for:

- *AC Immune, Alkermes, Alnylam, Alzheon, Anavex, Biogen, Brainstorm Cell, Cortexyme, Denali, EIP, ImmunoBrain Checkpoint, GemVax, Genentech, Green Valley, Novartis, Novo Nordisk, PeopleBio, Renew LLC, Roche.*

Is the international PI of trials with:

- *AC Immune, CogRx, FUJI-film/Toyama, IONIS, UCB, Vivoryon*

Is partner of:

- *LSP*



Learning Objectives

- Understand the difference between dementia and disease
- How neuroimaging can help to differentiate between diseases
- Which imaging techniques are available
- Which technique should be used when
- Sensitivity and specificity of the various techniques
 - In different disease types
 - In stages of the disease
- Know the limitations, risks and costs



Key Message

- Dementia is a syndrome with many causes, most of them located in the brain, and diagnosable with the help of various imaging techniques, in adjunct to complete (cognitive) neurological work up



References

- Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. *Lancet*. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/S0140-6736(20)32205-4. Epub 2021 Mar 2. PMID: 33667416
- van Oostveen WM, de Lange ECM. Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. *Int J Mol Sci*. 2021 Feb 20;22(4):2110. doi: 10.3390/ijms22042110. PMID: 33672696